R. Majeti
Molecular Biology · 2007–2018
A researcher in the Science corpus: 12 papers; trusts 4 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 108 citations into it
- Hematology — 62 citations into it; #87 of 225 by trust here, #46 by citations
- Immunology — 51 citations into it; #936 of 2,160 by trust here, #420 by citations
Whom R. Majeti trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Irving L. Weissman
- Jean C. Y. Wang
- Christopher Y. Park
- Catriona H. M. Jamieson
- Siddhartha Jaiswal
- G. Sauvageau
- A. Wagers
Who trusts R. Majeti overall
- M. R. Corces-Zimmerman
- M. Chao
- W. Pang
- Irving L. Weissman
- Siddhartha Jaiswal
- Ash A. Alizadeh
- J. Dick
- Derrick J. Rossi
- Catriona H. M. Jamieson
Papers from R. Majeti's perspective
Ordered by how strongly the researchers R. Majeti trusts endorse each paper. Same corpus, a different order for every researcher.
- Identification of human brain tumour initiating cells (Nature)
- Stem cells, cancer, and cancer stem cells (Nature)
- Targeting of CD44 eradicates human acute myeloid leukemic stem cells (Nature Medicine)
- CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells (Cell)
- Integrin-associated protein (CD47) and its ligands. (Trends in Cell Biology)
- Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. (Cell Stem Cell)
- The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor (Nature)
- Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells (Nature)
- Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. (Cell)
- Cancer stem cells: lessons from leukemia. (Trends in Cell Biology)
Their papers
- Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution (2016) — 1,038 citations
- CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells (2009) — 1,689 citations
- CRISPR/Cas9 Beta-globin Gene Targeting in Human Hematopoietic Stem Cells (2016) — 737 citations
- Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation (2018) — 609 citations
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma (2018) — 890 citations
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission (2014) — 717 citations
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors (2012) — 1,535 citations
- Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia (2012) — 706 citations
- Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47 (2010) — 737 citations
- Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma (2010) — 1,038 citations
- CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. (2009) — 1,544 citations
- Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. (2007) — 604 citations